Skip to main content

Advertisement

SpringerLink
Log in

Managing Hypertension in the Elderly: What is Different, What is the Same?

  • Elderly and Heart Disease (K. Dharmarajan, Section Editor)
  • Published:
Current Cardiovascular Risk Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

The goal is to discuss management of hypertension in the elderly.

Recent Findings

At 3.14-year follow-up of 2636 persons ≥75 years in the Systolic Blood Pressure Intervention Trial (SPRINT), compared with a systolic blood pressure (SBP) goal of <140 mmHg, a SBP goal of <120 mmHg reduced the primary endpoint of myocardial infarction, other acute coronary syndrome, stroke, heart failure, or cardiovascular death by 34% (p = 0.001), all-cause mortality by 33% (p = 0.009), heart failure by 38% (p = 0.003), and the primary outcome or death by 32% (p < 0.001). Absolute cardiovascular event rates were lower for the intensive treatment group within each frailty stratum. The incidence of serious adverse events was similar in both treatment groups.

Summary

The SPRINT trial provides very important information on the efficacy and safety of lowering the SBP to <120 mmHg in elderly adults with hypertension.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224–60.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents. Developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J am Coll Cardiol. 2011;57:2037–114.

    Article  PubMed  Google Scholar 

  3. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119:e21–e181.

    Article  PubMed  Google Scholar 

  4. Aronow WS, Ahmed MI, Ekundayo OJ, Allman RM, Ahmed A. A propensity-matched study of the association of PAD with cardiovascular outcomes in community-dwelling older adults. Am J Cardiol. 2009;103:130–5.

    Article  PubMed  Google Scholar 

  5. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortalty: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–13.

    Article  PubMed  Google Scholar 

  6. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). Jama. 1991;265:3255–64.

    Article  Google Scholar 

  7. Perry HM Jr, Davis BR, Price TR, Applegate WB, Fields WS, Guralnik JM, et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. The Systolic Hypertension in the Elderly Program (SHEP). Jama. 2000;284:465–71.

    Article  PubMed  Google Scholar 

  8. Kostis JB, Davis BR, Cutler J, Grimm RH Jr, Berge KG, Cohen JD, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. Jama. 1997;278:212–6.

    Article  CAS  PubMed  Google Scholar 

  9. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet. 1997;350:757–64.

    Article  CAS  PubMed  Google Scholar 

  10. Liu L, Wang J-G, Gong L, Liu G, Staessen JA. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens. 1998;16:1823–9.

    Article  CAS  PubMed  Google Scholar 

  11. Staessen JA, Gasowski J, Wang JG, Thijs L, Den Hond E, Boissel JP, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet. 2000;355:865–72.

    Article  CAS  PubMed  Google Scholar 

  12. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J med. 2008;358:1887–98.

    Article  CAS  PubMed  Google Scholar 

  13. Banach M, Bromfield S, Howard G, Howard VJ, Zanchetti A, Aronow WS, et al. Association of systolic blood pressure levels with cardiovascular events and all-cause mortality among older adults taking antihypertensive medication. Int J Cardiol. 2014;176:219–26.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Banach M, Zanchetti A, Bromfield S, Chlebus K, Howard G, Howard VJ, et al. What is targeted diastolic blood pressure in elderly patients-the results from the REasons for Geographic and Racial Differences in Stroke (REGARDS) cohort study (abstract). Eur Heart J. 2014;35(suppl 1):abstract 4799.

    Google Scholar 

  15. •• SPS3 Study Group, Benavente OR, Coffey CS, Conwitt R, Hart RG, McClure LA, et al. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet. 2013;(382):507–15. Compared to a systolic blood pressure of 138 mm Hg, a systolic blood pressure of 127 mm Hg in 3020 patients with recent lacunar stroke nonsignificantly reduced at 3.7-year follow-up all stroke by 19%, disabling or fatal stroke by 19%, and myocardial infarction or vascular death by 16% and significantly reduced intracerebral hemorrhage by 63% (p = 0.03)

  16. Oparil S. SPS3 evidence supports intensive blood pressure control. Circulation. 2016;133:552–4.

    PubMed  PubMed Central  Google Scholar 

  17. •• Wright JT, Jr WJD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J med. 2015;373:2103–16. Compared to a systolic blood pressure goal below 140 mm Hg, a systolic blood pressure goal below 120 mm Hg reduced in 9,361 persons at 3.26 years the primary composite outcome of myocardial infarction, other acute coronary syndrome, stroke, heart failure, or death from cardiovascular causes by 25% (p < 0.0-01), all-cause mortality by 27% ( p = 0.003), heart failure by 38% ( p = 0.002), death from cardiovascular causes by 43% (p = 0.005) ), and. the primary composite outcome or death by 22% ( p < 0.001)

    Article  CAS  PubMed  Google Scholar 

  18. •• Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM, et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years. A randomized clinical trial. Jama. 2016;315:2673–82. At 3.14-year median follow-up of 2,636 persons aged 75 years and older, mean age 79.9 years, compared with a systolic blood pressure goal of less than 140 mm Hg, a systolic blood pressure goal of less than 120 mm Hg reduced the primary endpoint of myocardial infarction, other acute coronary syndrome, stroke, heart failure, or cardiovascular death by 34% (p = 0.001), all-cause mortality by 33% (p = 0.009), heart failure by 38% (p = 0.003), and the primary outcome or death by 32% (p < 0.001)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Bress AP, Tanner RM, Hess R, Colantonio LD, Shimbo D, Muntner P. Generizability of SPRINT results to the U.S. adult population. J am Coll Cardiol. 2016;67:463–72.

    Article  PubMed  Google Scholar 

  20. •• Bress AP, Kramer H, Khatib R, Beddhu S, Cheung AK, Hess R, et al. Potential deaths averted and serious adverse events incurred from adoption of the SPRINT (Systolic Blood Pressure Intervention Trial) intensive blood pressure regimen in the United States. Projections from NHANES (National Health and Nutrition Examination Survey). Circulation. 2017;(135):1617–28. This study reported that intensive lowering of systolic blood pressure of all eligible United States adults could prevent 107,500 deaths per year and 46,100 cases of heart failure per year but cause an increase in serious adverse events

  21. Lonn EM, Bosch J, Jaramillo PL, Zhu J, Liu L, Pais P, et al. Blood pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J med. 2016;374:2009–20.

    Article  CAS  PubMed  Google Scholar 

  22. Whelton PK, Reboussin DM, Fine LJ. Comparing the SPRINT and the HOPE-3 blood pressure trial. JAMA Cardiol. 2016;1:855–6.

    Article  PubMed  Google Scholar 

  23. •• Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957–67. This meta-analysis demonstrated that every 10 mm Hg reduction in systolic blood pressure significantly reduced major cardiovascular events by 20%, coronary heart disease by 17%, stroke by 27%, and heart failure by 28%, which in the populations studied reduced all-cause mortality by 13%

    Article  PubMed  Google Scholar 

  24. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159–219.

    Article  PubMed  Google Scholar 

  25. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults. Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). Jama. 2014;311:507–20.

    Article  CAS  PubMed  Google Scholar 

  26. Wright JT Jr, Fine LJ, Lackland DT, Ogedegbe G, Dennison-Himmelfarb C. Evidence supporting a systolic blood pressure goal of less than 150 mm hg in patients aged 60 years or older: the minority view. Ann Intern med. 2014;160:499–503.

    Article  PubMed  Google Scholar 

  27. Krakoff LR, Gillespie RL, Ferdinand KC, Fergus IV, Akinboboye O, Williams KA, et al. 2014 hypertension recommendations from the Eighth Joint National Committee Members raise concerns for elderly black and female populations. J am Coll Cardiol. 2014;64:394–402.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Hackam DG, Quinn RR, Ravani P, Rabi DM, Dasgupta K, Daskalopoulou SS, et al. The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol. 2013;29:528–42.

    Article  PubMed  Google Scholar 

  29. •• Weber MA, Schiffrin EL White WB, Mann S, Lindholm LH, Kenerson JG, et al. Clinical practice guidelines for the management of hypertension in the community. A Statement by the American Society of Hypertension and the International Society of Hypertension. 2014; 16: 14–26. These guidelines recommend that the blood pressure should be lowered to less than 140/90 mm Hg in adults aged 60 to 79 years and to less than 150'90 mm Hg in adults aged 80 years and older .

  30. •• Rosendorff C, Lackland DT, Allison M, Aronow WS, Black HR, Blumenthal RS, et al. AHA/ACC/ASH scientific statement. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. J am Coll Cardiol. 2015;65:1998–2038. These guidelines recommend that the blood pressure should be reduced to less than 140/90 mm Hg in patients with coronary artery disease and with an acute coronary syndrome if they are aged 80 years and younger but to less than 150/90 mm Hg if they are older than 80 years of age

    Article  PubMed  Google Scholar 

  31. •• Padwal R, Rabi DM, Schiffrin EL. Recommendations for intensive blood pressure lowering in high-risk patients, the Canadian viewpoint. Hypertension. 2016;68:3–5. These Canadian guidelines recommend that high-risk adults aged 50 years and older with a systolic blood pressure of 130 mm Hg or higher obtained by an automated office blood pressure measurement should have a target systolic blood pressure goal of 120 mm Hg or lower

    Article  CAS  PubMed  Google Scholar 

  32. •• Gabb GM, Mangoni A, Anderson CS, Cowley D, Dowden JS, Golledge J, et al. Guidelines for the diagnosis and management of hypertension in adults—2016. Med J Australia. 2016;205:85–9. These Australian guidelines state that selected high cardiovascular risk persons should have a systolic blood pressure goal of less than 120 mm Hg to improve cardiovascular outcomes

    Article  PubMed  Google Scholar 

  33. •• Qaseem A, Wilt TJ, Rich R, Humphrey LL, Frost J, Forciea MA, et al., for the Clinical Guidelines Committee of the American College of Physicians and the Commission on Health of the Public and Science of the American academy of Family Physicians. Pharmacologic treatment of hypertension in adults aged 60 years or older to higher versus lower blood pressure targets: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern med. 2017;166:430–7. Adults aged 60 years and older with a systolic blood pressure of 150 mm Hg and higher should have their systolic blood pressure reduced to less than 150 mm Hg. Adults aged 60 years and older with a history of stroke or transient ischemic attack should have their systolic blood pressure reduced to less than 140 mm Hg. Adults aged 60 years and older at high cardiovascular risk should have their systolic blood pressure reduced to less than 140 mm Hg

  34. Law MR, Morris JK, Wald NJ. Use of BP lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665. doi:10.1136/bmj.b1665.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. American Diabetes Association. Position statement. Standards of Medical Care in Diabetes—2013. Diabetes Care. 2013;36(supplement 1):S11–S-66.

    Article  Google Scholar 

  36. KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Chapter 3. Blood pressure management in CKD ND patients without diabetes mellitus. Kidney Int Supplements. 2012;2:357–62.

    Article  Google Scholar 

  37. KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Chapter 4. Blood pressure management in CKD ND patients with diabetes mellitus. Kidney Int Supplements. 2012;2:363–9.

    Article  Google Scholar 

  38. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. The JNC 7 Report. Jama. 2003;289:2560–72.

    Article  CAS  PubMed  Google Scholar 

  39. Aronow WS. Current role of beta blockers in the treatment of hypertension. Expert Opin Pharmacotherap. 2010;11:2599–607.

    Article  CAS  Google Scholar 

  40. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. ACCF/AHA guidelines for the management of heart failure: executive summary. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American College of Chest Physicians, Heart Rhythm Society, and International Society for Heart and Lung Transplantation. Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation. J am Coll Cardiol. 2013;62:1495–539.

    Article  Google Scholar 

  41. Aronow WS. Might losartan reduce sudden cardiac death in diabetic patients with hypertension? Lancet. 2003;362:591–2.

    Article  PubMed  Google Scholar 

  42. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet. 2004;364:1684–9.

    Article  CAS  PubMed  Google Scholar 

  43. Erikkson S, Olofsson BO, Wester PO. Atenolol in the secondary prevention after stroke. Cerebrovasc dis. 1995;5:21–5.

    Article  Google Scholar 

  44. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes:UKPDS39. Br med J. 1998;317:713–20.

    Article  Google Scholar 

  45. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003.

    Article  CAS  PubMed  Google Scholar 

  46. Wilhelmsen L, Berglund G, Elmfeldt D, Fitzsimons T, Holzgreve H, Hosie J, et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens. 1987;5:561–72.

    Article  CAS  PubMed  Google Scholar 

  47. Oparil S, Lewis CE. Should patients with cardiovascular risk factors receive intensive treatment of hypertension to <120/80 mm target? A protagonist view from the SPRINT trial (Systolic Blood Pressure Intervention trial). Circulation. 2016;134:1208–310.

    Article  Google Scholar 

  48. Supiano MA, Williamson JD. Applying the Systolic Blood Pressure Intervention Trial results to older adults. Jags. 2017;65:15–21.

    Article  Google Scholar 

  49. ACCORD Study Group. Effects of intensive blood pressure control in type 2 diabetes. N Engl J med. 2010;362:1575–85.

    Article  Google Scholar 

  50. Jones DW, Weatherly L, Hall JE. SPRINT. What remains unanswered and where do we go from here? Hypertension. 2016;67:261–2.

    CAS  PubMed  Google Scholar 

  51. Margolis KL, O'Connor PJ, Morgan TM, Buse JB, Cohen RM, Cushman WS, et al. Outcomes of combined cardiovascular risk factor management strategies in type 3 diabetes: The ACCORD randomized trial. Diabetes Care. 2014;37:1721–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Soliman EZ, Byington RP, Bigger JT, Evans G, Okin PM, Goff DC Jr, et al. Effect of intensive blood pressure lowering on left ventricular hypertrophy in patients with diabetes mellitus: Action to Control Cardiovascular Risk in Diabetes Blood Pressure Trial. Hypertension. 2015;66:1123–9.

  53. Fleg JL, Evans GW, Margolis KL, Barzilay J, Basile JN, Bigger JT, et al. Orthostatic hypotension in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) Blood Pressure trial. Prevalence, incidence, and prognostic significance. Hypertension. 2016;68:888–95.

    Article  CAS  PubMed  Google Scholar 

  54. Aronow WS. Orthostatic hypotension in diabetics in the ACCORD (Action to control cardiovascular risk in diabetes) blood pressure trial. Hypertension. 2016;68:851–2.

    Article  CAS  PubMed  Google Scholar 

  55. Schiffrin EL, Calhoun DA, Flack JM. Do we need a new definition of hypertension after SPRINT? Am J Hypertens. 2016;29:1127–8.

    Article  PubMed  Google Scholar 

  56. Muntner P, Whelton PK. Using predicted cardiovascular disease risk in conjunction with blood pressure to guide antihypertensive medication treatment. J am Coll Cardiol. 2017;69:2446–56.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiology Division, Department of Medicine, New York Medical College/Westchester Medical Center, Macy Pavilion, Room 141, Valhalla, NY, 10595, USA

    Wilbert S. Aronow

Authors
  1. Wilbert S. Aronow
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wilbert S. Aronow.

Ethics declarations

Conflict of Interest

The author declare that he has no conflicts of interests to declare.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the author.

Additional information

This article is part of the Topical Collection on Elderly and Heart Disease

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Aronow, W.S. Managing Hypertension in the Elderly: What is Different, What is the Same?. Curr Cardiovasc Risk Rep 11, 22 (2017). https://doi.org/10.1007/s12170-017-0548-3

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s12170-017-0548-3

Keywords

Search

Navigation